Literature DB >> 12623858

Aminoglycoside prescribing and surveillance in cystic fibrosis.

Kelvin H-V Tan1, Michael Mulheran, Alan J Knox, Alan R Smyth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12623858     DOI： 10.1164/rccm.200109-012CC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  15 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  Minimizing the toxicity of aminoglycosides in cystic fibrosis.

Authors:  Alan R Smyth
Journal:  J R Soc Med       Date:  2010-07       Impact factor: 5.344

3.  Acute renal failure in people with cystic fibrosis.

Authors:  Kevin W Southern
Journal:  Thorax       Date:  2007-06       Impact factor: 9.139

Review 4.  Drug-Induced Ototoxicity: Diagnosis and Monitoring.

Authors:  Kathleen C M Campbell; Colleen G Le Prell
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

5.  Chirp-Evoked Otoacoustic Emissions and Middle Ear Absorbance for Monitoring Ototoxicity in Cystic Fibrosis Patients.

Authors:  Angela C Garinis; Douglas H Keefe; Lisa L Hunter; Denis F Fitzpatrick; Daniel B Putterman; Garnett P McMillan; Jeffrey A Gold; M Patrick Feeney
Journal:  Ear Hear       Date:  2018 Jan/Feb       Impact factor: 3.570

6.  Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.

Authors:  Michael Mulheran; Pauline Hyman-Taylor; Kelvin H-V Tan; Sarah Lewis; David Stableforth; Alan Knox; Alan Smyth
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 7.  -The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Int J Biol Markers       Date:  2011-09-21       Impact factor: 2.659

8.  The applicability of urinary creatinine as a method of specimen normalization in the cystic fibrosis population.

Authors:  Brandie D Wagner; Frank J Accurso; Theresa A Laguna
Journal:  J Cyst Fibros       Date:  2010-03-15       Impact factor: 5.482

9.  Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.

Authors:  Min Dong; Anna V Rodriguez; Chelsea A Blankenship; Gary McPhail; Alexander A Vinks; Lisa L Hunter
Journal:  J Antimicrob Chemother       Date:  2021-10-11       Impact factor: 5.790

10.  Sinonasal manifestations in cystic fibrosis.

Authors:  Karin P Q Oomen; Max M April
Journal:  Int J Otolaryngol       Date:  2012-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.